1. Home
  2. VSTM vs MAIA Comparison

VSTM vs MAIA Comparison

Compare VSTM & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Verastem Inc.

VSTM

Verastem Inc.

HOLD

Current Price

$4.37

Market Cap

470.7M

Sector

Health Care

ML Signal

HOLD

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

HOLD

Current Price

$1.37

Market Cap

77.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VSTM
MAIA
Founded
2010
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
470.7M
77.1M
IPO Year
2011
2022

Fundamental Metrics

Financial Performance
Metric
VSTM
MAIA
Price
$4.37
$1.37
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$16.50
N/A
AVG Volume (30 Days)
2.1M
495.3K
Earning Date
05-07-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
17.49
33.33
EPS
N/A
N/A
Revenue
$30,914,000.00
N/A
Revenue This Year
$282.64
N/A
Revenue Next Year
$72.25
N/A
P/E Ratio
N/A
N/A
Revenue Growth
209.14
N/A
52 Week Low
$4.00
$0.87
52 Week High
$11.25
$3.19

Technical Indicators

Market Signals
Indicator
VSTM
MAIA
Relative Strength Index (RSI) 37.62 55.69
Support Level $4.00 $1.23
Resistance Level $6.67 $1.46
Average True Range (ATR) 0.28 0.08
MACD -0.01 0.01
Stochastic Oscillator 28.40 89.19

Price Performance

Historical Comparison
VSTM
MAIA

About VSTM Verastem Inc.

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

Share on Social Networks: